{"ref-id":"L3002","title":"Cyclosporine Product Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050573s039,050574s047,050625s053lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L2953","title":"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm","parent_key":"BE0001032"}
{"ref-id":"L11097","title":"Novartis Monograph: Apo-Cyclosporine","url":"https://pdf.hres.ca/dpd_pm/00014004.PDF","parent_key":"BE0001066"}
{"ref-id":"L2953","title":"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm","parent_key":"BE0001004"}
{"ref-id":"L2953","title":"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm","parent_key":"BE0003659"}
{"ref-id":"L176","title":"Link","url":"http://www.pharmgkb.org/pathway/PA145011110","parent_key":"BE0003659"}
{"ref-id":"L11043","title":"FDA Approved Drug Products: Diflucan (fluconazole)","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019949s065,020090s047lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L3580","title":"Ranolazine FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021526s007lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L162","title":"Flockhart Table of Drug Interactions","url":"https://drug-interactions.medicine.iu.edu/Main-Table.aspx","parent_key":"BE0001032"}
{"ref-id":"L12114","title":"FDA Approved Drug Products: Morphine Sulfate Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022207s009lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L4849","title":"HIV insite, UCSF: Tenofovir Alafenamide","url":"http://hivinsite.ucsf.edu/InSite?page=ar-01-09","parent_key":"BE0001032"}
{"ref-id":"L11830","title":"FDA Approved Drug Products: Bactrim (sulfamethoxazole/trimethoprim) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017377s074lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L6319","title":"Proton Pump Inhibitors Inhibit Methotrexate Transport by Renal Basolateral Organic Anion Transporter hOAT3","url":"http://dmd.aspetjournals.org/content/dmd/42/12/2041.full.pdf","parent_key":"BE0003645"}
{"ref-id":"L8393","title":"Human P-glycoprotein differentially affects antidepressant drug transport: relevance to blood-brain barrier permeability","url":"https://academic.oup.com/ijnp/article/16/10/2259/653065","parent_key":"BE0001032"}
{"ref-id":"L175","title":"Link","url":"https://www.pharmgkb.org/pathway/PA150642262#","parent_key":"BE0001069"}
{"ref-id":"L3868","title":"FDA reports","url":"https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM421134.pdf","parent_key":"BE0001032"}
{"ref-id":"L3868","title":"FDA reports","url":"https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM421134.pdf","parent_key":"BE0001004"}
{"ref-id":"L2953","title":"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm","parent_key":"BE0003645"}
{"ref-id":"L7114","title":"Inhibition of Methotrexate Uptake via Organic Anion Transporters OAT1 and OAT3 by Glucuronides of Nonsteroidal Anti-inflammatory Drugs","url":"https://www.jstage.jst.go.jp/article/bpb/40/6/40_b16-00970/_pdf/-char/ja","parent_key":"BE0003645"}
{"ref-id":"L11139","title":"FDA Approved Drug Products: PEPCID (famotidine) tablets, for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019462s039lbl.pdf","parent_key":"BE0001066"}
{"ref-id":"L11139","title":"FDA Approved Drug Products: PEPCID (famotidine) tablets, for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019462s039lbl.pdf","parent_key":"BE0003645"}
{"ref-id":"L2953","title":"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm","parent_key":"BE0001069"}
{"ref-id":"L4082","title":"OAT1 and OAT3 (organic anion transporters 1 and 3)","url":"https://www.solvobiotech.com/transporters/oat1","parent_key":"BE0001066"}
{"ref-id":"L4082","title":"OAT1 and OAT3 (organic anion transporters 1 and 3)","url":"https://www.solvobiotech.com/transporters/oat1","parent_key":"BE0003645"}
{"ref-id":"L2953","title":"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm","parent_key":"BE0001042"}
{"ref-id":"L9227","title":"FDA Approved Drug Products: Prezista (darunavir) oral tablets/suspension","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021976s056,202895s027lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L4137","title":"Invega Trinza (Paliperidone palmitate) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207946s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L3954","title":"Invega (Paliperidone) FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021999s018lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L8138","title":"Colchicine FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022352s017lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L1162","title":"Empowerpharmacy","url":"https://www.empowerpharmacy.com/drugs/testosterone-propionate-injection.html","parent_key":"BE0001032"}
{"ref-id":"L11163","title":"FDA Approved Drug Products: Kaletra (lopinavir/ritonavir) for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021251s058,021906s053lbl.pdf","parent_key":"BE0001004"}
{"ref-id":"L6667","title":"FDA label, Zerbaxa","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206829lbl.pdf","parent_key":"BE0001066"}
{"ref-id":"L6670","title":"Clinical pharmacology and biopharmaceutics review","url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206829Orig1s000ClinPharmR.pdf","parent_key":"BE0003645"}
{"ref-id":"L6667","title":"FDA label, Zerbaxa","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206829lbl.pdf","parent_key":"BE0003645"}
{"ref-id":"L3952","title":"Plaquenil (hydroxychloroquine sulfate) - Drug Summary","url":"http://www.pdr.net/drug-summary/Plaquenil-hydroxychloroquine-sulfate-1911","parent_key":"BE0001032"}
{"ref-id":"L867","title":"Pharmaceuticals and Medical Devices Agency (PMDA): Topiroxostat review","url":"https://www.pmda.go.jp/files/000153624.pdf","parent_key":"BE0003645"}
{"ref-id":"L867","title":"Pharmaceuticals and Medical Devices Agency (PMDA): Topiroxostat review","url":"https://www.pmda.go.jp/files/000153624.pdf","parent_key":"BE0001066"}
{"ref-id":"L13532","title":"FDA Approved Drug Products: Ixempra (ixabepilone) kit for intravenous infusion","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022065s006lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L11929","title":"NCI Dictionary: Biricodar","url":"https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1653","parent_key":"BE0001032"}
{"ref-id":"L2953","title":"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm","parent_key":"BE0001067"}
{"ref-id":"L8048","title":"Pretomanid FDA label, August 2019","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212862s000lbl.pdf","parent_key":"BE0003645"}
{"ref-id":"L8057","title":"Pretomanid briefing document, FDA","url":"https://www.fda.gov/media/127592/download","parent_key":"BE0003645"}
{"ref-id":"L4105","title":"CAPRELSAB. (vandetanib) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022405s007lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L938","title":"European Medicines Agency (EMA): BESPONSA Summary of Product Characteristics","url":"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004119/WC500231261.pdf","parent_key":"BE0001032"}
{"ref-id":"L12633","title":"FDA Approved Products: Ocaliva (obeticholic acid) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207999s003lbl.pdf","parent_key":"BE0000703"}
{"ref-id":"L11932","title":"NCATS: Tariquidar","url":"https://drugs.ncats.io/substance/J58862DTVD","parent_key":"BE0001032"}
{"ref-id":"L4886","title":"Resolor (prucalopride) EMA label","url":"https://www.ema.europa.eu/documents/product-information/resolor-epar-product-information_en.pdf","parent_key":"BE0001032"}
{"ref-id":"L167","title":"JEVTANA - cabazitaxel","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa","parent_key":"BE0001032"}
{"ref-id":"L167","title":"JEVTANA - cabazitaxel","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa","parent_key":"BE0001067"}
{"ref-id":"L167","title":"JEVTANA - cabazitaxel","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa","parent_key":"BE0001004"}
{"ref-id":"L167","title":"JEVTANA - cabazitaxel","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa","parent_key":"BE0003659"}
{"ref-id":"L14201","title":"FDA Approved Drug Products: Brilinta Ticagrelor Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022433s028lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L11575","title":"FDA Approved Drug Products: DIFICID (fidaxomicin) tablets, for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213138lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L13994","title":"FDA Approved Products: Tekturna (Aliskiren) oral tablets and pellets","url":"https://www.tekturna.com/wp-content/uploads/2017/11/Tekturna_PCR-1.pdf","parent_key":"BE0001032"}
{"ref-id":"L4854","title":"NHIVC","url":"https://www.hiv.uw.edu/go/antiretroviral-therapy/drug-drug-interactions/core-concept/all","parent_key":"BE0001032"}
{"ref-id":"L13688","title":"FDA Approved Drug Products: Jardiance (empagliflozin) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204629s023lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L13688","title":"FDA Approved Drug Products: Jardiance (empagliflozin) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204629s023lbl.pdf","parent_key":"BE0001067"}
{"ref-id":"L13688","title":"FDA Approved Drug Products: Jardiance (empagliflozin) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204629s023lbl.pdf","parent_key":"BE0003645"}
{"ref-id":"L13688","title":"FDA Approved Drug Products: Jardiance (empagliflozin) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204629s023lbl.pdf","parent_key":"BE0001004"}
{"ref-id":"L13688","title":"FDA Approved Drug Products: Jardiance (empagliflozin) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204629s023lbl.pdf","parent_key":"BE0003659"}
{"ref-id":"L5089","title":"Olaparib New Zealand Data Sheet","url":"https://medsafe.govt.nz/profs/Datasheet/l/lynparzacap.pdf","parent_key":"BE0001032"}
{"ref-id":"L5089","title":"Olaparib New Zealand Data Sheet","url":"https://medsafe.govt.nz/profs/Datasheet/l/lynparzacap.pdf","parent_key":"BE0001067"}
{"ref-id":"L8453","title":"FDA Approved Drugs: Nintedanib","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205832s010lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L3675","title":"FDA Approved Drug Products: PROVAYBLUE (methylene blue) injection, for intravenous use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204630s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L1066","title":"Journal of Health Science","url":"http://jhs.pharm.or.jp/data/55(4)/55_540.pdf","parent_key":"BE0001032"}
{"ref-id":"L14099","title":"FDA Approved Drug Products: Artesunate Intravenous Injection","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf","parent_key":"BE0001067"}
{"ref-id":"L14099","title":"FDA Approved Drug Products: Artesunate Intravenous Injection","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L14099","title":"FDA Approved Drug Products: Artesunate Intravenous Injection","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf","parent_key":"BE0001004"}
{"ref-id":"L14099","title":"FDA Approved Drug Products: Artesunate Intravenous Injection","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf","parent_key":"BE0003645"}
{"ref-id":"L463","title":"UniProt","url":"http://www.uniprot.org/uniprot/Q92887","parent_key":"BE0001069"}
{"ref-id":"L464","title":"ChEMBL","url":"https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1646","parent_key":"BE0001069"}
{"ref-id":"L2287","title":"Australian Product Information: Sunvepra (Asunaprevir) Capsules","url":"http://www.medicines.org.au/files/bqpsunve.pdf","parent_key":"BE0001004"}
{"ref-id":"L2287","title":"Australian Product Information: Sunvepra (Asunaprevir) Capsules","url":"http://www.medicines.org.au/files/bqpsunve.pdf","parent_key":"BE0001042"}
{"ref-id":"L2287","title":"Australian Product Information: Sunvepra (Asunaprevir) Capsules","url":"http://www.medicines.org.au/files/bqpsunve.pdf","parent_key":"BE0001032"}
{"ref-id":"L2293","title":"Australian Public Assessment Report: Asunaprevir","url":"https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf","parent_key":"BE0001032"}
{"ref-id":"L769","title":"FDA Clinical Pharmacology and Biopharmaceutics Review","url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208073Orig1s000ClinPharmR.pdf","parent_key":"BE0003642"}
{"ref-id":"L769","title":"FDA Clinical Pharmacology and Biopharmaceutics Review","url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208073Orig1s000ClinPharmR.pdf","parent_key":"BE0001042"}
{"ref-id":"L6247","title":"Tafamadis SmPC EMA","url":"https://www.ema.europa.eu/en/documents/product-information/vyndaqel-epar-product-information_en.pdf","parent_key":"BE0001067"}
{"ref-id":"L6247","title":"Tafamadis SmPC EMA","url":"https://www.ema.europa.eu/en/documents/product-information/vyndaqel-epar-product-information_en.pdf","parent_key":"BE0001066"}
{"ref-id":"L6247","title":"Tafamadis SmPC EMA","url":"https://www.ema.europa.eu/en/documents/product-information/vyndaqel-epar-product-information_en.pdf","parent_key":"BE0003645"}
{"ref-id":"L12945","title":"FDA approved products: Tukysa (tucatinib) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf","parent_key":"BE0001067"}
{"ref-id":"L12945","title":"FDA approved products: Tukysa (tucatinib) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L6814","title":"Symdeko FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L9395","title":"FDA Approved Drug Products: Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf","parent_key":"BE0001067"}
{"ref-id":"L9338","title":"FDA Approved Drugs: Reyvow","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L9338","title":"FDA Approved Drugs: Reyvow","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf","parent_key":"BE0001067"}
{"ref-id":"L11941","title":"FDA Approved Drug Products: AEMCOLO (rifamycin) delayed-release tablets, for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210910s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L8237","title":"FDA Approved Drug Products: Istradefylline Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022075s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L8237","title":"FDA Approved Drug Products: Istradefylline Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022075s000lbl.pdf","parent_key":"BE0001067"}
{"ref-id":"L8237","title":"FDA Approved Drug Products: Istradefylline Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022075s000lbl.pdf","parent_key":"BE0001004"}
{"ref-id":"L8225","title":"Pharmaceuticals and Medical Devices Agency Japan: Report on Istradefylline","url":"https://www.pmda.go.jp/files/000153870.pdf","parent_key":"BE0001004"}
{"ref-id":"L8237","title":"FDA Approved Drug Products: Istradefylline Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022075s000lbl.pdf","parent_key":"BE0003659"}
{"ref-id":"L8237","title":"FDA Approved Drug Products: Istradefylline Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022075s000lbl.pdf","parent_key":"BE0001066"}
{"ref-id":"L13347","title":"FDA Approved Drug Products: Tabrecta (capmatinib) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L13347","title":"FDA Approved Drug Products: Tabrecta (capmatinib) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf","parent_key":"BE0001067"}
{"ref-id":"L12132","title":"EMA Summary of Product Characteristics: Isturisa (osilodrostat) oral tablets","url":"https://www.ema.europa.eu/en/documents/product-information/isturisa-epar-product-information_en.pdf","parent_key":"BE0001004"}
{"ref-id":"L12132","title":"EMA Summary of Product Characteristics: Isturisa (osilodrostat) oral tablets","url":"https://www.ema.europa.eu/en/documents/product-information/isturisa-epar-product-information_en.pdf","parent_key":"BE0001066"}
{"ref-id":"L12123","title":"FDA Approved Drug Products: Isturisa (osilodrostat) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf","parent_key":"BE0003645"}
{"ref-id":"L12144","title":"FDA Approved Products: Nexletol (bempedoic acid) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf","parent_key":"BE0001004"}
{"ref-id":"L12144","title":"FDA Approved Products: Nexletol (bempedoic acid) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf","parent_key":"BE0003659"}
{"ref-id":"L10863","title":"FDA Approved Drug Products: Dayvigo (lemborexant) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L6655","title":"New Mexico Cancer Alliance: Compassionate Use of Alpelisib","url":"https://clinicaltrials.gov/ProvidedDocs/82/NCT03941782/Prot_000.pdf","parent_key":"BE0001067"}
{"ref-id":"L6652","title":"FDA Approved Drug Products: Piqray (alpelisib) tablet","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L11938","title":"FDA Approved Drug Products: SEYSARA (sarecycline) tablets for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209521s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L1028","title":"FDA Reports","url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208772Orig1s000MultidisciplineR.pdf","parent_key":"BE0001067"}
{"ref-id":"L11971","title":"FDA Approved Drug Products: Nurtec ODT (rimegepant) orally disintegrating tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L11971","title":"FDA Approved Drug Products: Nurtec ODT (rimegepant) orally disintegrating tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf","parent_key":"BE0001067"}
{"ref-id":"L11971","title":"FDA Approved Drug Products: Nurtec ODT (rimegepant) orally disintegrating tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf","parent_key":"BE0001004"}
{"ref-id":"L11971","title":"FDA Approved Drug Products: Nurtec ODT (rimegepant) orally disintegrating tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf","parent_key":"BE0003645"}
{"ref-id":"L11971","title":"FDA Approved Drug Products: Nurtec ODT (rimegepant) orally disintegrating tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf","parent_key":"BE0003659"}
{"ref-id":"L12075","title":"Pharmaceuticals and Medical Devices Agency: Avigan (favipiravir) Review Report","url":"https://www.pmda.go.jp/files/000210319.pdf","parent_key":"BE0001032"}
{"ref-id":"L12075","title":"Pharmaceuticals and Medical Devices Agency: Avigan (favipiravir) Review Report","url":"https://www.pmda.go.jp/files/000210319.pdf","parent_key":"BE0001066"}
{"ref-id":"L12075","title":"Pharmaceuticals and Medical Devices Agency: Avigan (favipiravir) Review Report","url":"https://www.pmda.go.jp/files/000210319.pdf","parent_key":"BE0003645"}
{"ref-id":"L12075","title":"Pharmaceuticals and Medical Devices Agency: Avigan (favipiravir) Review Report","url":"https://www.pmda.go.jp/files/000210319.pdf","parent_key":"BE0004782"}
{"ref-id":"L8090","title":"FDA Approved Drug Products: Fedratinib Oral Capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L8090","title":"FDA Approved Drug Products: Fedratinib Oral Capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf","parent_key":"BE0001067"}
{"ref-id":"L8090","title":"FDA Approved Drug Products: Fedratinib Oral Capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf","parent_key":"BE0001004"}
{"ref-id":"L8090","title":"FDA Approved Drug Products: Fedratinib Oral Capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf","parent_key":"BE0003659"}
{"ref-id":"L12582","title":"FDA Approved Products: Zeposia (Ozanimod) oral capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf","parent_key":"BE0001067"}
{"ref-id":"L12582","title":"FDA Approved Products: Zeposia (Ozanimod) oral capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L14327","title":"FDA Approved Drug Products: Zepzelca (lurbinectedin) for intravenous injection","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L14327","title":"FDA Approved Drug Products: Zepzelca (lurbinectedin) for intravenous injection","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf","parent_key":"BE0001004"}
{"ref-id":"L14327","title":"FDA Approved Drug Products: Zepzelca (lurbinectedin) for intravenous injection","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf","parent_key":"BE0003659"}
{"ref-id":"L8093","title":"Xenleta FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211672s000,211673s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L11476","title":"FDA Approved Drug Products: Tazverik Tazemetostat Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211723s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L10872","title":"FDA Approved Drug Products: NUBEQA (darolutamide) tablets, for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf","parent_key":"BE0001067"}
{"ref-id":"L10872","title":"FDA Approved Drug Products: NUBEQA (darolutamide) tablets, for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L7883","title":"FDA Approved Drug Products: Turaliotm (pexidartinib) capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf","parent_key":"BE0001004"}
{"ref-id":"L7883","title":"FDA Approved Drug Products: Turaliotm (pexidartinib) capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf","parent_key":"BE0003659"}
{"ref-id":"L7883","title":"FDA Approved Drug Products: Turaliotm (pexidartinib) capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf","parent_key":"BE0001042"}
{"ref-id":"L10836","title":"FDA Approved Drug Products: Padcev (enfortumab vedotin-ejfv) for IV injection","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L539","title":"UniProt","url":"http://www.uniprot.org/uniprot/Q9Y6L6","parent_key":"BE0001004"}
{"ref-id":"L572","title":"ChEMBL","url":"https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1002","parent_key":"BE0001004"}
{"ref-id":"L572","title":"ChEMBL","url":"https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1002","parent_key":"BE0003659"}
{"ref-id":"L541","title":"UniProt","url":"http://www.uniprot.org/uniprot/Q9NPD5","parent_key":"BE0003659"}
{"ref-id":"L1052","title":"FDA Reports","url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208054Orig1s000PharmR.pdf","parent_key":"BE0001188"}
{"ref-id":"L581","title":"ChEMBL","url":"https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1096927","parent_key":"BE0001004"}
{"ref-id":"L581","title":"ChEMBL","url":"https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1096927","parent_key":"BE0003659"}
{"ref-id":"L582","title":"KEGG","url":"http://www.genome.jp/dbget-bin/www_bget?cpd:C09621","parent_key":"BE0003659"}
{"ref-id":"L540","title":"ChEMBL","url":"https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL57053","parent_key":"BE0003659"}
{"ref-id":"L13239","title":"FDA: Fact Sheet For Health Care Providers EUA of Remdesivir","url":"https://www.fda.gov/media/137566/download","parent_key":"BE0001004"}
{"ref-id":"L13239","title":"FDA: Fact Sheet For Health Care Providers EUA of Remdesivir","url":"https://www.fda.gov/media/137566/download","parent_key":"BE0001032"}
{"ref-id":"L13239","title":"FDA: Fact Sheet For Health Care Providers EUA of Remdesivir","url":"https://www.fda.gov/media/137566/download","parent_key":"BE0003659"}
{"ref-id":"L13239","title":"FDA: Fact Sheet For Health Care Providers EUA of Remdesivir","url":"https://www.fda.gov/media/137566/download","parent_key":"BE0000703"}
{"ref-id":"L13239","title":"FDA: Fact Sheet For Health Care Providers EUA of Remdesivir","url":"https://www.fda.gov/media/137566/download","parent_key":"BE0001188"}
{"ref-id":"L13239","title":"FDA: Fact Sheet For Health Care Providers EUA of Remdesivir","url":"https://www.fda.gov/media/137566/download","parent_key":"BE0003644"}
{"ref-id":"L13769","title":"FDA Approved Drug Products: QINLOCK (ripretinib) tablets, for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L13769","title":"FDA Approved Drug Products: QINLOCK (ripretinib) tablets, for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf","parent_key":"BE0001067"}
{"ref-id":"L10842","title":"FDA Approved Drug Products: ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L10842","title":"FDA Approved Drug Products: ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf","parent_key":"BE0001004"}
{"ref-id":"L10842","title":"FDA Approved Drug Products: ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf","parent_key":"BE0003659"}
{"ref-id":"L10842","title":"FDA Approved Drug Products: ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf","parent_key":"BE0000785"}
{"ref-id":"L10842","title":"FDA Approved Drug Products: ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf","parent_key":"BE0001067"}
{"ref-id":"L10914","title":"Upadacitinib Clinical Pharmacology and Biopharmaceutics Review(s) - FDA","url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf","parent_key":"BE0001032"}
{"ref-id":"L10914","title":"Upadacitinib Clinical Pharmacology and Biopharmaceutics Review(s) - FDA","url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf","parent_key":"BE0001067"}
{"ref-id":"L10914","title":"Upadacitinib Clinical Pharmacology and Biopharmaceutics Review(s) - FDA","url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000ClinPharmR.pdf","parent_key":"BE0001004"}
{"ref-id":"L13050","title":"FDA Approved Drug Products: PEMAZYRE (pemigatinib) tablets, for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L13050","title":"FDA Approved Drug Products: PEMAZYRE (pemigatinib) tablets, for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf","parent_key":"BE0001067"}
{"ref-id":"L10926","title":"FDA Approved Drug Products: Ubrelvy (ubrogepant) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L10926","title":"FDA Approved Drug Products: Ubrelvy (ubrogepant) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf","parent_key":"BE0001067"}
{"ref-id":"L10926","title":"FDA Approved Drug Products: Ubrelvy (ubrogepant) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf","parent_key":"BE0001004"}
{"ref-id":"L10926","title":"FDA Approved Drug Products: Ubrelvy (ubrogepant) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf","parent_key":"BE0003659"}
{"ref-id":"L10926","title":"FDA Approved Drug Products: Ubrelvy (ubrogepant) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf","parent_key":"BE0001066"}
{"ref-id":"L9395","title":"FDA Approved Drug Products: Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf","parent_key":"BE0001004"}
{"ref-id":"L9395","title":"FDA Approved Drug Products: Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf","parent_key":"BE0003659"}
{"ref-id":"L9395","title":"FDA Approved Drug Products: Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L13604","title":"FDA Approved Drug Products: Retevmo (selpercatinib) capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf","parent_key":"BE0001032"}
{"ref-id":"L13604","title":"FDA Approved Drug Products: Retevmo (selpercatinib) capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf","parent_key":"BE0001067"}